ImmunityBio, Inc. IBRX Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayableTrade.
The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about ImmunityBio, Inc.'s accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ImmunityBio, Inc.'s accounts payable?
- ImmunityBio, Inc. (IBRX) reported accounts payable of $3.9M in Q1 2026.
- How has ImmunityBio, Inc.'s accounts payable changed year-over-year?
- ImmunityBio, Inc.'s accounts payable decreased by 39.4% year-over-year, from $6.44M to $3.9M.
- What is the long-term trend for ImmunityBio, Inc.'s accounts payable?
- Over 3 years (2021 to 2024), ImmunityBio, Inc.'s accounts payable has grown at a -5.2% compound annual growth rate (CAGR), from -$3.72M to -$3.17M.